Advertisement

Role of Eicosanoids in Tumor Cell-Platelet-Endothelial Cell Interactions

  • Bruce W. Steinert
  • Bonnie F. Sloane
  • David G. Menter
  • John D. Crissman
  • John D. Taylor
  • Kenneth V. Honn

Abstract

Metastases represent perhaps the single most important hindrance to improved cancer patient survival. The formation of metastases is the culmination of a complex series of tumor cell-host interactions called the metastatic cascade (Figure 1; 1,2). During tumor progression, tumor cells become separated from the primary tumor mass and invade into the surrounding tissue. Occasionally, tumor cells will invade blood vessels or lymphatics (intravasation) and are readily disseminated throughout the host. A relatively small percentage of the circulating tumor cells will arrest at the vessel wall and invade into the surrounding tissue (extravasation) to establish a secondary tumor site (3–5). The interaction of the circulating tumor cells with host immune cells may result in destruction of the tumor cells, whereas interaction with host platelets and/or blood coagulation components may enhance the metastatic process. Evidence for the involvement of platelets in metastasis has been demonstrated by several investigators (for review see 6,7). Enhancement of tumor cell arrest and adhesion to the vessel wall by platelets has been postulated as the mechanism for this phenomenon, but its exact nature is undetermined. Because of the potent effects of arachidonic acid metabolites (i.e., prostacyclin and thromboxane A2) on platelet function, we have hypothesized that tumor cells shift the balance between these metabolites in favor of platelet aggregation (8). We have previously proposed the use of modifiers of arachidonic acid metabolism as antimetastatic agents, although the efficacy of antimetastatic therapy with these modifiers has been inconsistent. Prostacyclin (PGI2) has been recently shown to reduce the incidence of pulmonary.

Keywords

Circulate Tumor Cell Arachidonic Acid Metabolism Arachidonic Acid Metabolite Metastatic Cascade W256 Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    I.J. Fidler, D.M. Gersten and I.R. Hart The biology of cancer invasion and metastasis. Adv. Cancer Res. 28:149–250 (1985).CrossRefGoogle Scholar
  2. 2.
    G.L. Nicolson Cancer metastasis. Organ colonization and the cell surface properties of malignant cells. Biochem. Biophys. Acta 113–176 (1982).Google Scholar
  3. 3.
    L. Weiss, Cancer cell traffic from the lungs to the liver: an example of metastatic inefficiency. Int. Cancer 25:385–392 (1980).CrossRefGoogle Scholar
  4. 4.
    L. Weiss, Metastatic inefficiency. In: “Tumor Invasion and Metastasis” (L.A. Liotta and I.R. Hart, Eds), pp. 81–98. Martinus-Nijhoff, The Hague, 1982.CrossRefGoogle Scholar
  5. 5.
    L. Weiss, Overview of the metastatic cascade. In: “Hemostatic Mechanisms and Metastasis” (K.V. Honn and B.F. Sloane, Eds), pp. 15–38. Martinus-Nijhoff, The Hague, 1983.Google Scholar
  6. 6.
    K.V. Honn and B.F. Sloane (Eds.), “Hemostatic Mechanisms and Metastasis”. Martinus Nijhoff, the Hague, 1983.Google Scholar
  7. 7.
    G.A. Jamieson (Ed.), “Interaction of Platelets and Tumor Cells”. Alan R. Liss, New York, 1982.Google Scholar
  8. 8.
    K.V. Honn, W.D. Busse and B.F. Sloane, Commentary. Prostacyclin and thomboxanes. Implications for their role in tumor cell metastasis. Biochem. Pharmacol. 32:1–11 (1983).PubMedCrossRefGoogle Scholar
  9. 9.
    K.V. Honn, D.G. Menter, J.M. Onoda, J.D. Taylor and B.F. Sloane. Role of Prostacyclin as a natural deterrent to hematogenous tumor metastasis. In: “Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects” (G.L. Nicolson and L. Milas, Eds), pp. 361–388. Raven Press, New York, 1984.Google Scholar
  10. 10.
    K.V. Honn, B. Cicone and A. Skoff, Prostacyclin: a potent antimetastatic agent. Science 212:1270–1272 (1981).PubMedCrossRefGoogle Scholar
  11. 11.
    K.V. Honn and J.R. Dunn, Nafazatrom (Bay g 6575) inhibition of tumor lipoxygenase activity and cellular proliferation. FEES Lett. 139: 65–68 (1982).CrossRefGoogle Scholar
  12. 12.
    K.V. Honn, Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. lin. Metastases 1:103–114 (1983).Google Scholar
  13. 13.
    K.V. Honn, D. Menter, C. Moilanen, P.G. Cavanaugh, J.D. Taylor and B.F. Sloane, Role of prostacyclin and thromboxanes in tumor cell-platelet-vessel wall interactions. In: “Protective Agents in Cancer” (D.C.H. Mrian and T.F. Slater, Eds.), pp. 57–79. Academic Press, New York, 1983.Google Scholar
  14. 14.
    D.G. Menter, J.M. Onoda, J.D. Taylor and K.V. Honn. Effects of prostacyclin on tumor cell-induced platelet aggregation. Cancer Res. 44:450–456, 1984.PubMedGoogle Scholar
  15. 15.
    K.V. Honn and B.F. Sloane, Prostacyclin, thromboxanes and hematogenous metastasis. M. Prostaglandin Thromboxane Leukotriene 12:313–318 (1983).Google Scholar
  16. 16.
    K.V. Honn, D. Menter, P.G. Cavanaugh, G. Neagos, D. Moilanen, J.D. Taylor and B. F. Sloane, A review of prostaglandins and the treatment of tumor metastasis. Acta Clin. Belg. 38:53–67 (1983).PubMedGoogle Scholar
  17. 17.
    S. Moncada and J.R. Vane, The discovery of prostacyclin (PGX): a fresh insight into arachidonic acid metabolism. In: “Biochemical Aspects of Prostaglandins and Thromboxanes” (N. Kharasch and J. Fried, Eds.), pp. 155–177. Academic Press, New York, 1977.Google Scholar
  18. 18.
    J. Fantone, S. Kunkel and J. Varani, Inhibition of tumor cell adherence by prostaglandins. In: “Prostaglandins and Cancer” (T.J. Powles, R.S. Bookman, K.V. Honn and P. Ramwell, Eds.), pp. 673–677. Alan R. Liss, New York, 1982.Google Scholar
  19. 19.
    Y. Hara, M. Steiner and M.G. Baldini. Characterization of the platelet aggregating activity of tumor cells. Cancer Res. 111:1217–1222 (1980).Google Scholar
  20. 20.
    J.A. Frangos, L.V. Mclntire, S.G. Eskin and C.L. Ives, Flow effects on prostacyclin production by cultured human endothelial cells. Science 227:1477–1479 (1985).PubMedCrossRefGoogle Scholar
  21. 21.
    C.F. Dewey Jr., Effect of fluid flow on living vascular cells. In: Proceedings of Poster Communications, 7th International Symposium on Athersclerosis, p. 190. Int. Atherosclerosis Soc., 1984.Google Scholar
  22. 22.
    W.E. Stehbens, Hemodynamics and atherosclerosis. Biorheology 19:95–101 (1983).Google Scholar
  23. 23.
    D.G. Menter, B.W. Steinert, J.M. Onoda, J.D. Taylor and K.V. Honn. Development of a new aggregometry model using microcarrier grown endothelial cells to examine tumor cell-platelet-endothelial cell interactions. J. Cell Biol. 103:471a (1986)Google Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Bruce W. Steinert
    • 1
  • Bonnie F. Sloane
    • 2
  • David G. Menter
    • 3
  • John D. Crissman
    • 4
  • John D. Taylor
    • 3
  • Kenneth V. Honn
    • 1
    • 3
  1. 1.Departments of Radiation OncologyWayne State UniversityDetroitUSA
  2. 2.Departments of PharmacologyWayne State UniversityDetroitUSA
  3. 3.Departments of Biological SciencesWayne State UniversityDetroitUSA
  4. 4.Departments of PathologyWayne State UniversityDetroitUSA

Personalised recommendations